ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

https://www.globenewswire.com/news-release/2023/05/24/2675357/0/en/ClearPoint-Neuro-and-UCB-Enter-License-Agreement-for-Gene-Therapy-Drug-Delivery.html

https://www.ftserussell.com/resources/russell-reconstitution CLPT findet sich aktuell auf der vorläufigen Liste zur Aufnahme in den Russell 3000 Ende Juni.

ClearPoint Neuro Reports Second Quarter 2023 Results https://finance.yahoo.com/news/clearpoint-neuro-reports-second-quarter-200500897.html

ClearPoint Neuro Reports Third Quarter 2023 Results https://www.globenewswire.com/news-release/2023/11/09/2777830/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2023-Results.html Biologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8M

https://www.globenewswire.com/news-release/2023/04/18/2649556/0/en/ClearPoint-Neuro-Announces-Agreement-with-NE-Scientific-to-Integrate-Gene-Therapy-Infusion-Coverage-Tool-into-ClearPoint-Maestro-Brain-Model.html

https://www.globenewswire.com/news-release/2023/03/28/2636196/0/en/ClearPoint-Neuro-Announces-Exclusive-Multi-Year-Licensing-Agreement-with-UCSF-for-Innovative-Intra-Cerebral-Cellular-Delivery-Platform.html

https://ir.clearpointneuro.com/news-events/press-releases/detail/1082/clearpoint-neuro-reports-fourth-quarter-and-full-year-2022

https://www.globenewswire.com/news-release/2023/01/11/2587014/25687/en/ClearPoint-Neuro-Reports-Fourth-Quarter-and-Full-Year-2022-Preliminary-Revenue-Results-and-Guidance-for-Full-Year-2023-Revenue.html

=00=

https://www.globenewswire.com/news-release/2022/12/12/2571981/0/en/ClearPoint-Neuro-Announces-First-Patient-Enrolled-in-Glioblastoma-Trial-Using-ClearPoint-Prism-Neuro-Laser-Therapy-System-at-Sk%C3%A5ne-University-Hospital-in-Sweden.html

ClearPoint Neuro GAAP EPS of -$0.15, revenue of $5.1M https://seekingalpha.com/news/3904123-clearpoint-neuro-gaap-eps-of-0_15-revenue-of-5_1m • ClearPoint Neuro press release (NASDAQ:CLPT): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M. • CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M. • Cash and short-term investments totaled $40.5M as of Sept 30, 2022. • CLPT said three new products were cleared by FDA in the quarter and are in the process of being deployed in limited market releases before the end of the year. • "We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions." - President and CEO Joe Burnett

ClearPoint Neuro Reports Third Quarter 2022 Results https://www.globenewswire.com/news-release/2022/11/08/2551424/25687/en/ClearPoint-Neuro-Reports-Third-Quarter-2022-Results.html Company Reaffirms 2022 Revenue Forecast

https://www.globenewswire.com/news-release/2022/09/23/2521573/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Prism-Neuro-Laser-Therapy-System.html

https://www.globenewswire.com/news-release/2022/09/19/2518720/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-Software-Version-2-1.html